Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

◆상품코드 : IRTNTR20288
◆발행일 : 2018년 2월
◆페이지수 : 73
◆보고서 형식 : PDF / 영문
◆납품 방식 : Email
◆조사대상 지역 : 글로벌
◆산업분야 : 미분류
◆발행회사(조사회사) : Technavio
◆판매회사 : H&I글로벌리서치(주)
◆판매가격 옵션
Single User¥392,000 -> 환산 ₩3,920,000견적의뢰/구매/질문FORM
Five User¥448,000 -> 환산 ₩4,480,000견적의뢰/구매/질문FORM
Enterprise License¥560,000 -> 환산 ₩5,600,000견적의뢰/구매/질문FORM
※지불하실 금액은 상기금액이며, 세금 및 배송료는 없습니다.
※지불은 선불결제 방식이며, 신용카드결제 또는 계좌입금(국내/해외)이 선택가능합니다.
※구매의사를 FORM기입 또는 E메일로 연락주시면 담당자가 회신 드리겠습니다.
※배송은 입금 확인 후, E메일로 납품드리며, 일반적으로 당일~2일정도 소요됩니다.
※가격옵션 설명 : (Single User : 귀사내에서 1명만 사용가능 / Five User, Multi User : 귀사내에서 5명까지 사용가능 / Site License, Corporate License : 동일국내에서 인원제한없이 사용가능 / Global Site License, Enterprise License : 지역상관없이 인원제한없이 사용/공유 가능한 라이센스). 자세한 설명은 이용안내 페이지를 참고하세요.


[조사보고서 개요]

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for ovarian cancer including molecules at various development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as route of administration and target.
Key questions answered in the report include
• What are the gene therapy molecules in the various development stages for ovarian cancer?
• What are the companies that are currently involved in the development of gene therapy molecules for ovarian cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule.

[조사보고서 목차]

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GENE THERAPY FOR OVARIAN CANCER: AN INSIGHT
• Introduction

PART 05: MAJOR REGULATORY AUTHORITIES
• US
• Europe
• Japan
• Australia
• China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS
• Mid-stage molecules (Phase II and I/II), 2017
• Early-stage molecules (Phase I), 2017
• Inactive molecules, 2017

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 10: THERAPEUTIC ASSESSMENT (BY TARGET)

PART 11: KEY COMPANIES
• Active companies: Category and parameters
• APPENDIX
• List of abbreviations


Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules by vendors
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: p53 gene therapy
Exhibit 07: Clinical trials description of p53 gene
Exhibit 08: Overview: Ofranergene obadenovec
Exhibit 09: Clinical trials description of Ofranergene obadenovec
Exhibit 10: Overview: GEN-1
Exhibit 11: Clinical trials description of GEN-1
Exhibit 12: Overview: LOAd703
Exhibit 13: Clinical trials description of LOAd703
Exhibit 14: Overview: ONCOS-102
Exhibit 15: Clinical trials description of ONCOS-102
Exhibit 16: Overview: Aglatimagene besadenovec
Exhibit 17: Clinical trials description of Aglatimagene besadenovec
Exhibit 18: Overview: TBI-1301
Exhibit 19: Clinical trials description of TBI-1301
Exhibit 20: Overview: BC-819
Exhibit 21: Clinical trials description of BC-819
Exhibit 22: Overview: MetXia
Exhibit 23: Overview: Gene therapy for ovarian cancer
Exhibit 24: Analysis by type of ovarian cancer
Exhibit 25: Overview of indication
Exhibit 26: Assessment by RoA
Exhibit 27: Segmentation of pipeline by stage and RoA
Exhibit 28: Assessment by target
Exhibit 29: Vendor landscape
Exhibit 30: Segmentation of companies
Exhibit 31: Overview: Advantagene, 2017
Exhibit 32: Overview: CELSION, 2017
Exhibit 33: Overview: Lokon Pharma, 2017
Exhibit 34: Overview: SiBiono GeneTech, 2017
Exhibit 35: Overview: Takara Bio, 2017
Exhibit 36: Overview: Targovax, 2017
Exhibit 37: Overview: Vascular Biogencies, 2017



[보고서에 포함된 내용]
세계시장규모, 세그멘트별 시장규모, 시장동향, 시장예측, 관련 기업정보 등

[면책사항]
http://www.globalresearch.kr/disclaimer

★조사보고서 [Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report]에 관해서 E메일 문의 연락
◆H&I글로벌리서치의 고객기업(예)◆